<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00444080</url>
  </required_header>
  <id_info>
    <org_study_id>14967</org_study_id>
    <nct_id>NCT00444080</nct_id>
  </id_info>
  <brief_title>Comparison of Ex-PRESSTM Mini Glaucoma Shunt to Trabeculectomy in Subjects With Open Angle Glaucoma</brief_title>
  <official_title>A Multi Center Study Comparing the Ex-PRESSTM Mini Glaucoma Shunt to Trabeculectomy in Subjects With Open Angle Glaucoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Virginia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Virginia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective randomized trial to compare the safety and efficacy of the Ex-PRESS to&#xD;
      trabeculectomy in patients with open angle glaucoma who failed medical or are allergic to&#xD;
      medical treatment and for which filtering surgery is indicated. Surgical success was defined&#xD;
      as 5 mmHg ≤ intraocular pressure ≤ 18 mmHg, with or without medications, without further&#xD;
      glaucoma surgery. Postoperative intraocular pressure, number of medications, complications&#xD;
      and success rates were followed for 2 years.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2006</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Postoperative Intraocular Pressure</measure>
    <time_frame>assessed at 1d, 1w, 1m, 3m, 6m, 12m, 18m, 24m. 24 months reported</time_frame>
    <description>Mean postoperative intraocular pressure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Medications</measure>
    <time_frame>assessed at 1d, 1w, 1m, 3m, 6m, 12m, 18m, 24m; 24 months reported</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety - Incidence of Adverse Events</measure>
    <time_frame>24 months</time_frame>
    <description>Comparison of the incidence of all adverse events that occur during the intra-operative and postoperative periods between the two study arms. More than 1 complication may have occurred in the same subject.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy - The Number of Participants With Qualified and Complete Success</measure>
    <time_frame>24 months</time_frame>
    <description>The secondary effectiveness measure will be qualified and complete success rate defined as IOP≤18mmHg with or without medications in the test group as compared to qualified and complete success rate in the concurrent control group at 24 month</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Glaucoma</condition>
  <arm_group>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects undergoing trabeculectomy with the use of Mitomycin C</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects undergoing Ex-PRESS Under Scleral Flap implantation procedure with the use of Mitomycin C</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Trabeculectomy</intervention_name>
    <description>Standard trabeculectomy procedure&#xD;
Creation of a fornix or limbal based conjunctival flap in upper quadrants&#xD;
Creation of a limbal-based scleral flap extending into clear cornea&#xD;
Delicate application of MMC solution onto sclerectomy bed. (MMC concentration 0.4mg/ml for 1-3 minutes)&#xD;
Creation of fistula 1mm x 2mm in size&#xD;
Iridectomy&#xD;
Suturing the scleral flap&#xD;
Repositioning of conjunctiva with sutures After procedure, antibiotics &amp; steroids are administered topically; eye is covered with a pad - patient is discharged.</description>
    <arm_group_label>Control Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Ex-PRESS mini shunt</intervention_name>
    <description>Ex-PRESS implantation procedure:&#xD;
Creation of a fornix or limbal based conjunctival flap in upper quadrants&#xD;
Creation of limbal-based scleral flap extending into clear cornea&#xD;
Delicate application of MMC solution onto sclerectomy bed. (MMC concentration 0.4mg/ml for 1-3 minutes)&#xD;
Penetration into anterior chamber using 23-25G needle, halfway between the white sclera and clear cornea (in the center of the grey zone);creation of track incision at limbus&#xD;
Prior to implantation, a thorough mobility check should be performed&#xD;
Implantation of Ex-PRESS implant loaded on its introducer, through that pre-incision&#xD;
Withdrawal of introducer&#xD;
Tucking plate under the scleral flap, and verification of its position&#xD;
Suturing scleral flap After implantation procedure, antibiotics &amp; steroids administered topically; eye is covered with a pad - patient is discharged.</description>
    <arm_group_label>Treatment Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult subject over the age of 18&#xD;
&#xD;
          -  Subject diagnosed with open angle glaucoma (POAG, PXFG or PDSG) or ocular hypertension&#xD;
&#xD;
          -  Subject is a candidate for filtering surgery with intraoperative anti-metabolites&#xD;
&#xD;
          -  IOP &gt; 18 mmHg on maximum tolerated medial therapy based on two measurements taken 1&#xD;
             hour apart at the same visit.&#xD;
&#xD;
          -  Subject willing to attend all follow-up evaluations&#xD;
&#xD;
          -  Subject willing to sign informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject diagnosed with: PACG, NTG, secondary glaucoma, neovascular glaucoma&#xD;
&#xD;
          -  Subject has history of glaucoma surgery (filtering, glaucoma drainage device, cyclo&#xD;
             destructive procedures)&#xD;
&#xD;
          -  Subject has history of penetrating keratoplasty (PKP)&#xD;
&#xD;
          -  Subject underwent large incision extra capsular cataract extraction&#xD;
&#xD;
          -  Subject had cataract phacoemulsification within the last month&#xD;
&#xD;
          -  Subject has a visually significant cataract that is planned for extraction at the time&#xD;
             of filtering surgery or within 12 months thereafter&#xD;
&#xD;
          -  Any ocular disease or history in the operated eye other than glaucoma and cataract,&#xD;
             such as uveitis, ocular infection, severe dry eye, severe blepharitis , active&#xD;
             proliferative retinopathy, ICE syndrome, epithelial or fibrous down growth, aphakia,&#xD;
             and ocular pathology that may interfere with accurate IOP measurements&#xD;
&#xD;
          -  Subject has vitreous present in the anterior chamber for which vitrectomy is&#xD;
             anticipated&#xD;
&#xD;
          -  IOP of ≤18mmHg&#xD;
&#xD;
          -  Subject participates in any other concurrent ocular investigation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter A. Netland, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Virginia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143-0730</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dean A. McGee Eye Institute</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wills EYE Institute</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19066</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allegheny Ophthalmic &amp; Orbital Associates, P.C.</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Tennessee</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38163</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osler Eyecare</name>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <zip>L5B 1N5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://pubmed.ncbi.nlm.nih.gov/24210765/</url>
    <description>Study results indexed on Pub Med</description>
  </link>
  <results_reference>
    <citation>Netland PA, Sarkisian SR Jr, Moster MR, Ahmed II, Condon G, Salim S, Sherwood MB, Siegfried CJ. Randomized, prospective, comparative trial of EX-PRESS glaucoma filtration device versus trabeculectomy (XVT study). Am J Ophthalmol. 2014 Feb;157(2):433-440.e3. doi: 10.1016/j.ajo.2013.09.014. Epub 2013 Nov 7.</citation>
    <PMID>24210765</PMID>
  </results_reference>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>March 5, 2007</study_first_submitted>
  <study_first_submitted_qc>March 5, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 7, 2007</study_first_posted>
  <results_first_submitted>August 27, 2020</results_first_submitted>
  <results_first_submitted_qc>September 21, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">October 14, 2020</results_first_posted>
  <last_update_submitted>September 21, 2020</last_update_submitted>
  <last_update_submitted_qc>September 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Virginia</investigator_affiliation>
    <investigator_full_name>Peter Netland, MD</investigator_full_name>
    <investigator_title>Vernah Scott Moyston Professor, Chair, Department of Ophthalmology</investigator_title>
  </responsible_party>
  <keyword>Ex-PRESS</keyword>
  <keyword>TRABECULECTOMY</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 5, 2011</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/80/NCT00444080/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Control Arm</title>
          <description>Subjects undergoing trabeculectomy with the use of Mitomycin C&#xD;
Trabeculectomy: Standard trabeculectomy procedure&#xD;
Creation of a fornix or limbal based conjunctival flap in upper quadrants&#xD;
Creation of a limbal-based scleral flap extending into clear cornea&#xD;
Delicate application of MMC solution onto sclerectomy bed. (MMC concentration 0.4mg/ml for 1-3 minutes)&#xD;
Creation of fistula 1mm x 2mm in size&#xD;
Iridectomy&#xD;
Suturing the scleral flap&#xD;
Repositioning of conjunctiva with sutures After procedure, antibiotics &amp; steroids are administered topically; eye is covered with a pad - patient is discharged.</description>
        </group>
        <group group_id="P2">
          <title>Treatment Arm</title>
          <description>Subjects undergoing Ex-PRESS Under Scleral Flap implantation procedure with the use of Mitomycin C&#xD;
Ex-PRESS mini shunt: Ex-PRESS implantation procedure:&#xD;
Creation of a fornix or limbal based conjunctival flap in upper quadrants&#xD;
Creation of limbal-based scleral flap extending into clear cornea&#xD;
Delicate application of MMC solution onto sclerectomy bed. (MMC concentration 0.4mg/ml for 1-3 minutes)&#xD;
Penetration into anterior chamber using 23-25G needle, halfway between the white sclera and clear cornea (in the center of the grey zone);creation of track incision at limbus&#xD;
Prior to implantation, a thorough mobility check should be performed&#xD;
Implantation of Ex-PRESS implant loaded on its introducer, through that pre-incision&#xD;
Withdrawal of introducer&#xD;
Tucking plate under the scleral flap, and verification of its position&#xD;
Suturing scleral flap After implantation procedure, antibiotics &amp; steroids administered topically; eye is covered with a pad.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="61"/>
                <participants group_id="P2" count="59"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="61"/>
                <participants group_id="P2" count="59"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Control Arm</title>
          <description>Subjects undergoing trabeculectomy with the use of Mitomycin C&#xD;
Trabeculectomy: Standard trabeculectomy procedure&#xD;
Creation of a fornix or limbal based conjunctival flap in upper quadrants&#xD;
Creation of a limbal-based scleral flap extending into clear cornea&#xD;
Delicate application of MMC solution onto sclerectomy bed. (MMC concentration 0.4mg/ml for 1-3 minutes)&#xD;
Creation of fistula 1mm x 2mm in size&#xD;
Iridectomy&#xD;
Suturing the scleral flap&#xD;
Repositioning of conjunctiva with sutures After procedure, antibiotics &amp; steroids are administered topically; eye is covered with a pad - patient is discharged.</description>
        </group>
        <group group_id="B2">
          <title>Treatment Arm</title>
          <description>Subjects undergoing Ex-PRESS Under Scleral Flap implantation procedure with the use of Mitomycin C&#xD;
Ex-PRESS mini shunt: Ex-PRESS implantation procedure:&#xD;
Creation of a fornix or limbal based conjunctival flap in upper quadrants&#xD;
Creation of limbal-based scleral flap extending into clear cornea&#xD;
Delicate application of MMC solution onto sclerectomy bed. (MMC concentration 0.4mg/ml for 1-3 minutes)&#xD;
Penetration into anterior chamber using 23-25G needle, halfway between the white sclera and clear cornea (in the center of the grey zone);creation of track incision at limbus&#xD;
Prior to implantation, a thorough mobility check should be performed&#xD;
Implantation of Ex-PRESS implant loaded on its introducer, through that pre-incision&#xD;
Withdrawal of introducer&#xD;
Tucking plate under the scleral flap, and verification of its position&#xD;
Suturing scleral flap After implantation procedure, antibiotics &amp; steroids administered topically; eye is covered with a pad.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="61"/>
            <count group_id="B2" value="59"/>
            <count group_id="B3" value="120"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69.4" spread="11.6"/>
                    <measurement group_id="B2" value="67.8" spread="10.4"/>
                    <measurement group_id="B3" value="68.6" spread="11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="55"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Postoperative Intraocular Pressure</title>
        <description>Mean postoperative intraocular pressure</description>
        <time_frame>assessed at 1d, 1w, 1m, 3m, 6m, 12m, 18m, 24m. 24 months reported</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control Arm</title>
            <description>Subjects undergoing trabeculectomy with the use of Mitomycin C&#xD;
Trabeculectomy: Standard trabeculectomy procedure&#xD;
Creation of a fornix or limbal based conjunctival flap in upper quadrants&#xD;
Creation of a limbal-based scleral flap extending into clear cornea&#xD;
Delicate application of MMC solution onto sclerectomy bed. (MMC concentration 0.4mg/ml for 1-3 minutes)&#xD;
Creation of fistula 1mm x 2mm in size&#xD;
Iridectomy&#xD;
Suturing the scleral flap&#xD;
Repositioning of conjunctiva with sutures After procedure, antibiotics &amp; steroids are administered topically; eye is covered with a pad - patient is discharged.</description>
          </group>
          <group group_id="O2">
            <title>Treatment Arm</title>
            <description>Subjects undergoing Ex-PRESS Under Scleral Flap implantation procedure with the use of Mitomycin C&#xD;
Ex-PRESS mini shunt procedure:&#xD;
Creation of a fornix or limbal based conjunctival flap in upper quadrants&#xD;
Creation of limbal-based scleral flap extending into clear cornea&#xD;
Delicate application of MMC solution onto sclerectomy bed. (MMC concentration 0.4mg/ml for 1-3 minutes)&#xD;
Penetration into anterior chamber using 23-25G needle, halfway between the white sclera and clear cornea (in the center of the grey zone);creation of track incision at limbus&#xD;
Prior to implantation, a thorough mobility check should be performed&#xD;
Implantation of Ex-PRESS implant loaded on its introducer, through that pre-incision&#xD;
Withdrawal of introducer&#xD;
Tucking plate under the scleral flap, and verification of its position&#xD;
Suturing scleral flap After implantation procedure, antibiotics &amp; steroids administered topically; eye is covered with a pad - patient is discharged.</description>
          </group>
        </group_list>
        <measure>
          <title>Postoperative Intraocular Pressure</title>
          <description>Mean postoperative intraocular pressure</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="59"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.6" spread="7.1"/>
                    <measurement group_id="O2" value="14.7" spread="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Medications</title>
        <time_frame>assessed at 1d, 1w, 1m, 3m, 6m, 12m, 18m, 24m; 24 months reported</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control Arm</title>
            <description>Subjects undergoing trabeculectomy with the use of Mitomycin C</description>
          </group>
          <group group_id="O2">
            <title>Treatment Arm</title>
            <description>Subjects undergoing Ex-PRESS Under Scleral Flap implantation procedure with the use of Mitomycin C</description>
          </group>
        </group_list>
        <measure>
          <title>Medications</title>
          <units>number of medications</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="59"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="1.2"/>
                    <measurement group_id="O2" value="0.9" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety - Incidence of Adverse Events</title>
        <description>Comparison of the incidence of all adverse events that occur during the intra-operative and postoperative periods between the two study arms. More than 1 complication may have occurred in the same subject.</description>
        <time_frame>24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control Arm</title>
            <description>Subjects undergoing trabeculectomy with the use of Mitomycin C&#xD;
Trabeculectomy: Standard trabeculectomy procedure&#xD;
Creation of a fornix or limbal based conjunctival flap in upper quadrants&#xD;
Creation of a limbal-based scleral flap extending into clear cornea&#xD;
Delicate application of MMC solution onto sclerectomy bed. (MMC concentration 0.4mg/ml for 1-3 minutes)&#xD;
Creation of fistula 1mm x 2mm in size&#xD;
Iridectomy&#xD;
Suturing the scleral flap&#xD;
Repositioning of conjunctiva with sutures After procedure, antibiotics &amp; steroids are administered topically; eye is covered with a pad - patient is discharged.</description>
          </group>
          <group group_id="O2">
            <title>Treatment Arm</title>
            <description>Subjects undergoing Ex-PRESS Under Scleral Flap implantation procedure with the use of Mitomycin C&#xD;
Ex-PRESS mini shunt implantation procedure:&#xD;
Creation of a fornix or limbal based conjunctival flap in upper quadrants&#xD;
Creation of limbal-based scleral flap extending into clear cornea&#xD;
Delicate application of MMC solution onto sclerectomy bed. (MMC concentration 0.4mg/ml for 1-3 minutes)&#xD;
Penetration into anterior chamber using 23-25G needle, halfway between the white sclera and clear cornea (in the center of the grey zone);creation of track incision at limbus&#xD;
Prior to implantation, a thorough mobility check should be performed&#xD;
Implantation of Ex-PRESS implant loaded on its introducer, through that pre-incision&#xD;
Withdrawal of introducer&#xD;
Tucking plate under the scleral flap, and verification of its position&#xD;
Suturing scleral flap After implantation procedure, antibiotics &amp; steroids administered topically; eye is covered with a pad - patient is discharged.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety - Incidence of Adverse Events</title>
          <description>Comparison of the incidence of all adverse events that occur during the intra-operative and postoperative periods between the two study arms. More than 1 complication may have occurred in the same subject.</description>
          <units>complications</units>
          <param>Number</param>
          <units_analyzed>eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="59"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.013</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Efficacy - The Number of Participants With Qualified and Complete Success</title>
        <description>The secondary effectiveness measure will be qualified and complete success rate defined as IOP≤18mmHg with or without medications in the test group as compared to qualified and complete success rate in the concurrent control group at 24 month</description>
        <time_frame>24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control Arm</title>
            <description>Subjects undergoing trabeculectomy with the use of Mitomycin C&#xD;
Trabeculectomy: Standard trabeculectomy procedure&#xD;
Creation of a fornix or limbal based conjunctival flap in upper quadrants&#xD;
Creation of a limbal-based scleral flap extending into clear cornea&#xD;
Delicate application of MMC solution onto sclerectomy bed. (MMC concentration 0.4mg/ml for 1-3 minutes)&#xD;
Creation of fistula 1mm x 2mm in size&#xD;
Iridectomy&#xD;
Suturing the scleral flap&#xD;
Repositioning of conjunctiva with sutures After procedure, antibiotics &amp; steroids are administered topically; eye is covered with a pad - patient is discharged.</description>
          </group>
          <group group_id="O2">
            <title>Treatment Arm</title>
            <description>Subjects undergoing Ex-PRESS Under Scleral Flap implantation procedure with the use of Mitomycin C&#xD;
Ex-PRESS mini shunt implantation procedure:&#xD;
Creation of a fornix or limbal based conjunctival flap in upper quadrants&#xD;
Creation of limbal-based scleral flap extending into clear cornea&#xD;
Delicate application of MMC solution onto sclerectomy bed. (MMC concentration 0.4mg/ml for 1-3 minutes)&#xD;
Penetration into anterior chamber using 23-25G needle, halfway between the white sclera and clear cornea (in the center of the grey zone);creation of track incision at limbus&#xD;
Prior to implantation, a thorough mobility check should be performed&#xD;
Implantation of Ex-PRESS implant loaded on its introducer, through that pre-incision&#xD;
Withdrawal of introducer&#xD;
Tucking plate under the scleral flap, and verification of its position&#xD;
Suturing scleral flap After implantation procedure, antibiotics &amp; steroids administered topically; eye is covered with a pad - patient is discharged.</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy - The Number of Participants With Qualified and Complete Success</title>
          <description>The secondary effectiveness measure will be qualified and complete success rate defined as IOP≤18mmHg with or without medications in the test group as compared to qualified and complete success rate in the concurrent control group at 24 month</description>
          <units>participants</units>
          <param>Number</param>
          <units_analyzed>eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="59"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Control Arm</title>
          <description>Subjects undergoing trabeculectomy with the use of Mitomycin C</description>
        </group>
        <group group_id="E2">
          <title>Treatment Arm</title>
          <description>Subjects undergoing Ex-PRESS Under Scleral Flap implantation procedure with the use of Mitomycin C</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Shallow anterior chamber</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="61"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Surgically treated cataract</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="61"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Hyphema</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="61"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Early wound leak</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="61"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Peter A. Netland, MD, PhD</name_or_title>
      <organization>University of Virginia</organization>
      <phone>434-982-1086</phone>
      <email>pan9c@virginia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

